This Week in NEJM

Premium

In NEJM this week, a team of European researchers reports its assessment of JAK inhibitor ruxolitinib versus the best available therapy for the treatment of myelofibrosis, a form of chronic leukemia. The team assigned 219 myelofibrosis patients to receive either ruxolitinib or the best available therapy, and found that 28 percent of the patients in the ruxolitinib group had at least a 35 percent reduction in spleen volume, compared to 0 percent in the best available treatment group.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.